Home | Life Sciences Intellectual Property Review
Nov 7, 2024 · Dexcom suffers second patent revocation at hands of UPC. The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills. Unified Patent Court.
Latest News & Features | Life Sciences Intellectual Property Review
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages. 5 November 2024. Americas.
Biotechnology | Life Sciences Intellectual Property Review
15 October 2024 Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.
Americas | Life Sciences Intellectual Property Review
13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Generics | Life Sciences Intellectual Property Review
All features. 2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent. 28 March 2024 Judge disagrees that barrier against generic drug makers should be ...
CRISPR | Life Sciences Intellectual Property Review
9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
EPO’s new examination guidelines: what you need to know
Apr 6, 2021 · A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.
Magazine Archive | Life Sciences Intellectual Property Review
Magazine Archive. Click the thumbnails below to view the Life Sciences IP Review magazines. LSIPR Spring/Summer 2022. Spring is here and the UK government is marking it by airing its Genetic Technology (Precision Breeding) Bill, promising to breathe new life into an area apparently suffocated by EU red tape. LSIPR new recruit Sarah Speight asks ...
The future of precision medicine part 1: challenges and …
Jun 13, 2018 · The promise of precision medicine has been extolled by researchers and clinicians for some time, but as sequencing costs continue to fall, sophistication of data analysis and patient stratification increases and data science and artificial intelligence (AI) begin to partner with the life sciences industry in earnest, that promise now seems closer than ever to realisation.
The value of secrecy for big pharma | Life Sciences Intellectual ...
Jun 23, 2016 · The value of secrecy for big pharma. The approval of the EU trade secrets directive and enactment of the Defend Trade Secrets Act (DTSA) in the US, both in May, were intended for stronger protection of trade secrets in the world’s most developed markets. The aim of the directive was to harmonise national trade secret laws of all EU member ...